Free tool
FAERS Monitor: Imfinzi
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761069 or its brand name (Imfinzi, Durvalumab). Reports on generic versions are filed under their own applications.
Reports
21,581
Serious
20,621
96% of reports
Hospitalization
6,299
Death reported
6,844
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death4,160
- malignant neoplasm progression1,703
- pneumonitis900
- radiation pneumonitis812
- diarrhoea700
- pyrexia670
- off label use616
- pneumonia500
- dyspnoea495
- interstitial lung disease491
- fatigue484
- asthenia478
- anaemia477
- rash460
- neutrophil count decreased420
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 8 |
| 2017 | 168 |
| 2018 | 769 |
| 2019 | 1,362 |
| 2020 | 1,456 |
| 2021 | 1,718 |
| 2022 | 1,511 |
| 2023 | 2,836 |
| 2024 | 3,709 |
| 2025 | 4,001 |
| 2026 | 4,043 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,578 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| radiation pneumonitisSignal | 812 | 595.0 | 545.8 | 298,648 |
| pneumonitisSignal | 900 | 33.3 | 31.2 | 27,251 |
| malignant neoplasm progressionSignal | 1,703 | 16.5 | 15.7 | 24,428 |
| neutrophil count decreasedSignal | 420 | 10.1 | 9.2 | 3,421 |
| interstitial lung diseaseSignal | 491 | 10.0 | 9.1 | 3,924 |
| deathSignal | 4,160 | 4.7 | 4.6 | 12,669 |
| anaemiaSignal | 477 | 2.4 | 2.2 | 407 |
| pyrexia | 670 | 1.9 | 1.8 | 283 |
| pneumonia | 500 | 1.5 | 1.4 | 86 |
| asthenia | 478 | 1.2 | 1.1 | 22 |
| diarrhoea | 700 | 1.1 | 1.0 | 2 |
| rash | 460 | 1.0 | 0.9 | 0 |
| dyspnoea | 495 | 0.9 | 0.8 | 13 |
| off label use | 616 | 0.7 | 0.6 | 92 |
| fatigue | 484 | 0.6 | 0.6 | 129 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.